|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...
Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.
The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug. An independent ...
Examining Orient Paper Inc’s (AMEX:ONP) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.
NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
When Carver Bancorp Inc (NASDAQ:CARV) announced its most recent earnings (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
The S&P 500’s top gainers on April 12 were: Incyte (INCY) gained 5.3%. Micron Technology (MU) gained 4.2%. Host Marriott Financial Trust (HST) gained 4.1%. Deere & Company (DE) gained 4.1%. Discovery (DISCK) gained 3.9%. Incyte
Incyte (INCY) popped to the top of among S&P 500 stock performers, helped by an analyst upgrade. Incyte added $3.54, or 5.3%, to $69.83. The S&P 500 gained 21.80 points, or 0.83%, to 2663.99. UBS's Carter ...
In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.
On April 6, 2018, Incyte (INCY) stock fell nearly 20%, triggered by news of the failure of the clinical trial for its skin cancer drug. The trial is for the assessment of the combo-therapy approach of Incyte’s epacadostat and Merck’s (MRK) Keytruda for the treatment of skin cancer. The Phase 3 trial results were unexpectedly found to yield unsuccessful results since it did not achieve the main goal of the study.